HCRN GI19-414

Study Name
HCRN GI19-414
ClinicalTrials.gov Identifier (if applicable)
NCT04895046
Clinical Trial Category (check all that apply)
  • Beyond First Line Therapy
  • Targeted Therapy
  • Immunotherapy
Study Center
Institution Name
Emory University
City
Atlanta
State
Georgia
Country
United States
List additional Institutions (include address, phone number, and website)
This study will be opened at additional locations through the Hoosier Cancer Research Network. Participating sites will be listed on the following web page as they open the study: https://hoosiercancer.org/clinical-trials/trial/hcrn-gi19-414/
Study Contacts
Principal Investigator
Walid Shaib, MD
P.I. Phone
(404) 778-8016
P.I. Email
walid.labib.shaib@emory.edu
Study Coordinator
Robyn Lillie
Study Coordinator Phone
(317) 921-2050
Study Coordinator Email
rlillie@hoosiercancer.org
OVERVIEW – in layman’s terms (150 words max)
This research study is aimed to find out if cholangiocarcinoma patients who have a certain type of cancer mutation and responded to platinum-based chemotherapy will benefit from the combination of niraparib (targeted therapy) and dostarlimab (immune therapy).
Enrollment
47
Study Start Date
09/01/2021
Estimated Completion Date
09/01/2023